Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79946.300.1324%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Journey Medical Corp

DERMNASDAQ
Trade with Public
Trade with Public
$7.86
-0.04-0.51%
At close: Sep 4, 5:00 PM EST
$8.05
0.192.42%
After Hours: Sep 4, 9:30 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Journey Medical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Journey Medical (DERM).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$12Upside to Avg. PT+44.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026B. Riley SecuritiesMayank MamtaniPT RaiseBuy$12→$15
Mar 26, 2026HC Wainwright & Co.Brandon FolkesMaintainedBuy$13
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15

B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $13

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $13.
Benzinga Newsdesk

PRO
Lake Street Maintains Buy on Journey Medical, Raises Price Target to $13

Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $13.
Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $12

B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $12.
Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9

Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $9.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved